» Articles » PMID: 17533024

Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2007 May 30
PMID 17533024
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Secondary hyperparathyroidism is a common complication in children receiving hemodialysis. Active vitamin D is an effective therapy, but its use is often limited by hypercalcemia and increased calcium x phosphorus (Ca x P) product. Paricalcitol, a selective vitamin D receptor activator, causes less sustained hypercalcemia and increase in Ca x P product than calcitriol and has been used effectively in adult hemodialysis patients.

Study Design: Double blind, placebo-controlled.

Setting & Participants: Hemodialysis units and pediatric subjects receiving hemodialysis.

Intervention: After a washout period of 2 to 6 weeks, 29 subjects aged 5 to 19 years received either paricalcitol or placebo for up to 12 weeks (0.04 mug/kg if initial intact parathyroid hormone [iPTH] level < 500 pg/mL [ng/L]; 0.08 mug/kg if initial iPTH level > 500 pg/mL [ng/L]). The dose was increased by 0.04 mug/kg every 2 weeks until there was a 30% decrease in iPTH level from baseline or calcium level greater than 11 mg/dL (>2.74 mmol/L) or Ca x P product greater than 75 mg(2)/dL(2) (>6.04 mmol(2)/L(2)).

Outcomes & Measurements: Two consecutive 30% decreases from baseline in iPTH levels and safety of paricalcitol, including hypercalcemia and increase in Ca x P product.

Results: 60% of the paricalcitol group had 2 consecutive 30% decreases from baseline iPTH levels compared with 21% in the placebo group (P = 0.06). The paricalcitol group had a mean decrease in iPTH level of 164 pg/mL (ng/L), whereas the placebo group had a mean increase of 238 pg/mL (ng/L; P = 0.03). There was no difference from baseline to final visit in calcium, phosphorus, or Ca x P product values in either group.

Limitations: Low power to detect differences in safety between groups and a short-term study.

Conclusion: Paricalcitol decreased iPTH levels in children receiving hemodialysis with no significant changes in serum calcium, phosphorus, or Ca x P product values during the course of the study.

Citing Articles

Significance of the Vitamin D Receptor on Crosstalk with Nuclear Receptors and Regulation of Enzymes and Transporters.

Noh K, Chow E, Quach H, Groothuis G, Tirona R, Pang K AAPS J. 2022; 24(4):71.

PMID: 35650371 DOI: 10.1208/s12248-022-00719-9.


Brazilian guidelines for chronic kidney disease-mineral and bone metabolism disorders in children and adolescents.

Abreu A, Soeiro E, Bedram L, Andrade M, Lopes R J Bras Nefrol. 2021; 43(4 Suppl 1):680-692.

PMID: 34910806 PMC: 8823923. DOI: 10.1590/2175-8239-JBN-2021-S114.


Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.

Zhang Z, Cai L, Wu H, Xu X, Fang W, He X Front Public Health. 2021; 9:712027.

PMID: 34368073 PMC: 8333861. DOI: 10.3389/fpubh.2021.712027.


Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Shroff R, Wan M, Nagler E, Bakkaloglu S, Cozzolino M, Bacchetta J Nephrol Dial Transplant. 2017; 32(7):1114-1127.

PMID: 28873971 PMC: 5837664. DOI: 10.1093/ndt/gfx080.


Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.

Hu X, Shang J, Yuan W, Zhang S, Jiang Y, Zhao B Herz. 2017; 43(6):518-528.

PMID: 28835982 DOI: 10.1007/s00059-017-4605-y.